Hypersensitivity Vasculitis

What is Hypersensitivity vasculitis?

Hypersensitivity vasculitis (HV) is often used to describe different types of vasculitis related to drug reactions, skin disorders or allergic vasculitis; however this is not always the correct use of the term.

The American College of Rheumatology established a list of criteria for the classification of HV. The criteria are:

  1. older than 16 years of age
  2. use of a drug before the development of symptoms
  3. skin rash
  4. biopsy of the skin rash that shows neutrophils, a type of white blood cells, around a small vessel

It should be noted that having three or more of these criteria does not always distinguish HV from other forms of vasculitis, particularly when the only or first symptom of vasculitis is a skin rash.

The presence of a skin rash, usually red spots, is the main symptom in HV. A biopsy of these skin spots reveals inflammation of the small blood vessels, called a leukocytoclastic vasculitis.

What causes Hypersensitivity vasculitis?

HV may be caused by a specific drug or occur in association with an infection, but it may also be idiopathic, meaning there is no known cause. Although drugs are the most common cause, drug-induced vasculitis is a poorly defined disorder.

The drugs that are most frequently listed as being associated with the development of HV include: penicillin, cephalosporin, sulfonamide, some medicines used to control blood pressure (loop and thiazide-type diuretics), phenytoin and allopurinol. Infections that may be associated with HV include hepatitis B or C virus, chronic infection with bacteria and HIV virus.

What are the symptoms?

The major symptoms of HV, in addition to a skin rash, are joint pains and increasing size of lymph nodes. In most patients, symptoms begin 7 to 10 days after the exposure to the drug or infection, but can be as short as two to seven days in some people.

Organ involvement in addition to the skin rash is very rare, but can be severe. Kidney inflammation and even more rarely liver, lung, heart and brain injury have occurred in patients with HV.

Symptoms of kidney involvement may not be noticed by the patient, but can be evaluated by a doctor looking at a urine sample for small amounts of blood and protein.

Kidney failure is not common. Kidney failure can be ‘acute’, meaning there is a fast loss of kidney function, but supportive treatment with dialysis can be done for a few days or weeks and kidney function returns. In some cases, ‘chronic’ kidney failure occurs, requiring an ongoing need for dialysis because the kidneys do not recover their normal function.

What is the treatment?

If a drug may have caused HV, then discontinuation of that specific drug usually leads to the disappearance of symptoms within a few days or weeks. If an infection caused the hypersensitivity, then treatment of the infection usually results in the disappearance of symptoms.

In some patients, especially those with ongoing infections, there may be ongoing or ‘chronic’ symptoms of HV. Drugs used to manage the skin rash and joint pains associated with HV might include corticosteroids and/or nonsteroidal anti-inflammatory drugs.

In patients with more severe or ongoing skin rashes that are not due to infection, drugs such as colchicine, antihistamines, and dapsone (or a combination of these drugs) may be helpful to control symptoms. Patients with disease in organs beyond the skin should be referred to a specialty doctor such as a nephrologist if the kidneys are involved.

Revision: September 2012

Click here to get the Hypersensitivity Vasculitis brochure in PDF format

Key Resources:

About Author: joseph

Medical Search Tools

Enter your search terms in this tool and the results will open in a new tab or window.

Participation in Clinical Trials is one way you can help advance research into finding better treatments and perhaps even a cure for vasculitis!
Learn how you can participate in clinical trials - National Institutes of Health

VCRC-VF Fellowship Program

The Vasculitis Clinical Research Consortium-Vasculitis Foundation Fellowship is a mentored training program of up to two years for physician-investigators who have a strong interest in vasculitis and wish to pursue a period of specialized training with an emphasis on clinical and/or translational patient-oriented clinical investigation.

The trainee will undertake the Fellowship between 2014-2019 at a VCRC-affiliated site in North America that has an established distinct clinical and research program in vasculitis and availability of senior faculty mentors.

"The Vasculitis Foundation is committed to creating greater awareness and interest in vasculitis," said Joyce Kullman, executive director of the VF. "We hope that the VCRC-VF Fellowship will encourage medical professionals to pursue careers in patient care and research linked to vasculitis."

To support the VCRC-VF Fellowship, please visit the donate page.

Medical Institutions

The Vasculitis Foundation encourages vasculitis patients to seek expert medical care for diagnosis and treatment of the disease. The VF works closely with vasculitis experts and centers around the world to ensure patients have access to the most up-to-date medical care.

The Vasculitis Clinical Research Consortium (VCRC) is an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research in different forms of vasculitis and improving the care of patients with vasculitis.